These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. [The cytotoxic effect of the thrombocytes from patients with mycosis fungoides and Kaposi's sarcoma]. Faradzhev ZG; Bolvacheva AV; Bykovskaia SN Vestn Dermatol Venerol; 1990; (11):34-6. PubMed ID: 2288150 [TBL] [Abstract][Full Text] [Related]
44. Kaposi's sarcoma in a young man in absence of AIDS or other known causes of immune suppression. Calzavara-Pinton P; Cattaneo R; Franceschini F; Airò P Boll Ist Sieroter Milan; 1987; 66(3):239-42. PubMed ID: 3435654 [TBL] [Abstract][Full Text] [Related]
45. Immune response to basal cell and squamous cell carcinomas. Grimwood RE Immunol Ser; 1989; 46():789-98. PubMed ID: 2488879 [TBL] [Abstract][Full Text] [Related]
46. [Delayed skin reaction in a group of 400 hospital patients: control study (author's transl)]. Orriols R; Morell F; Fité E; Ruiz J; Tornos C; Sanz R; Morera J Med Clin (Barc); 1981 Oct; 77(6):240-2. PubMed ID: 7321638 [TBL] [Abstract][Full Text] [Related]
47. Histogenesis of Kaposi's sarcoma associated with AIDS: a histologic, immunohistochemical and enzyme histochemical study. Hashimoto H; Müller H; Falk S; Stutte HJ Pathol Res Pract; 1987 Oct; 182(5):658-68. PubMed ID: 3684778 [TBL] [Abstract][Full Text] [Related]
48. The prognostic significance of delayed hypersensitivity to dinitrochlorobenzene and mechlorethamine hydrochloride in cutaneous T cell lymphoma. Vonderheid EC; Ekbote SK; Kerrigan K; Kalmanson JD; Van Scott EJ; Rook AH; Abrams JT J Invest Dermatol; 1998 Jun; 110(6):946-50. PubMed ID: 9620303 [TBL] [Abstract][Full Text] [Related]
49. [Cellular immunodeficiency in superficial mycoses and cutaneous viroses]. Honeyman J; Saavedra T; Villagra R; Cabezas AM; Awad P Med Cutan Ibero Lat Am; 1981; 9(3):179-82. PubMed ID: 7026933 [TBL] [Abstract][Full Text] [Related]
50. Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy. Pellet C; Chevret S; Blum L; Gauvillé C; Hurault M; Blanchard G; Agbalika F; Lascoux C; Ponscarme D; Morel P; Calvo F; Lebbé C J Invest Dermatol; 2001 Oct; 117(4):858-63. PubMed ID: 11676823 [TBL] [Abstract][Full Text] [Related]
51. [Immune reactions in assessing the disease prognosis in soft tissue sarcomas]. Klimenkov AA; Kadagidze ZG; Gladikov IuV Vopr Onkol; 1979; 25(1):3-8. PubMed ID: 425395 [TBL] [Abstract][Full Text] [Related]
52. Human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) DNA in Kaposi's sarcoma lesions, AIDS Kaposi's sarcoma cell lines, endothelial Kaposi's sarcoma simulators, and the skin of immunosuppressed patients. Dictor M; Rambech E; Way D; Witte M; Bendsöe N Am J Pathol; 1996 Jun; 148(6):2009-16. PubMed ID: 8669485 [TBL] [Abstract][Full Text] [Related]
53. Kaposi's sarcoma: a review and recent developments. Safai B; Good RA Clin Bull; 1980; 10(2):62-9. PubMed ID: 6249516 [No Abstract] [Full Text] [Related]